Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 99

Sort by

Sort Order Select

Journal Articles

North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need

Naveen Pemmaraju, Hagop Kantarjian, Kendra Sweet, Eunice Wang, Jayastu Senapati, Nathaniel R. Wilson, Marina Konopleva, Arthur E. Frankel, Vikas Gupta, Ruben Mesa, Matthew Ulrickson, Edward Gorak, Sumeet Bhatia, Tulin Budak-Alpdogan, James Mason, Maria Teresa Garcia-Romero, Norma Lopez-Santiago, Gabriela Cesarman-Maus, Pankit Vachhani, Sangmin Lee, Vijaya Raj Bhatt, William Blum, Roland B. Walter, Dale Bixby, Ivana Gojo, Madeleine Duvic, Raajit K. Rampal, Marcos de Lima, James Foran, Amir T. Fathi, Aric Cameron Hall, Meagan A. Jacoby, Jeffrey Lancet, Gabriel Mannis, Anthony S. Stein, Alice Mims, David Rizzieri, Rebecca Olin, Alexander Perl, Gary Schiller, Paul Shami, Richard M. Stone, Stephen Strickland, Matthew J. Wieduwilt, Naval Daver, Farhad Ravandi, Sumithira Vasu, Monica Guzman, Gail J. Roboz, Joseph Khoury, Muzaffar Qazilbash, Phyu P. Aung, Branko Cuglievan, Yazan Madanat, Mohamed A. Kharfan-Dabaja, Anna Pawlowska, Justin Taylor, Martin Tallman, Prajwal Dhakal, Andrew A. Lane

Blood (2023) 141 (6): 567–578.

https://doi.org/10.1182/blood.2022017865

Published: 2023

Journal Articles

Phase IIa Study of Adding Itacitinib to Tacrolimus/Sirolimus Gvhd Prophylaxis after Fludarabine/Melphalan-Based Conditioning Hematopoietic Cell Transplantation for Acute Leukemias, Myelodysplastic Syndrome, or Myelofibrosis

Blood (2022) 140 (Supplement 1): 1872–1874.

https://doi.org/10.1182/blood-2022-170323

Published: 2022

Journal Articles

Outcome of Patients Undergoing Hematopoietic Cell Transplantation for TP53-Mutated Acute Leukemias and MDS: Effect of Conditioning and GvHD Prophylaxis Regimens Intensity

Blood (2022) 140 (Supplement 1): 10624–10626.

https://doi.org/10.1182/blood-2022-167757

Published: 2022

Journal Articles

Tagraxofusp, an Anti-CD123 Therapy, in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm and Prior or Concomitant Hematologic Malignancies: Subgroup Analysis of a Pivotal Trial

Naveen Pemmaraju, Marina Konopleva, Kendra Sweet, Anthony S. Stein, Sumithira Vasu, David A Rizzieri, Eunice S. Wang, Hagop Kantarjian, Christopher L. Brooks, Carole Paley, Tariq I. Mughal, Andrew A. Lane

Blood (2022) 140 (Supplement 1): 6155–6157.

https://doi.org/10.1182/blood-2022-159970

Published: 2022

Journal Articles

A Phase 1b Study of IDH Inhibition with Enasidenib and MEK Inhibition with Cobimetinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia Who Have Co-Occurring IDH2 and RAS Signaling Gene Mutations

Brian J Ball, Eytan Stein, Marjorie Robbins, Jianying Zhang, Ross L. Levine, Timothy Synold, Anthony S. Stein, Guido Marcucci, Yilun Liu, Alexey V Danilov

Blood (2022) 140 (Supplement 1): 11761–11762.

https://doi.org/10.1182/blood-2022-170820

Published: 2022

Journal Articles

An Open-Label, First-in-Human, Dose-Escalation Study of SAR443579 Administered As Single Agent By Intravenous Infusion in Patients with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-Cell Acute Lymphoblastic Leukemia (B-ALL) or High-Risk Myelodysplasia (HR-MDS)

Anthony S. Stein, Ashish Bajel, Shaun Fleming, Mojca Jongen-Lavrencic, Sylvain Garciaz, Abhishek Maiti, Nicolas Boissel, Stephane De Botton, Gerwin A. Huls, David C. de Leeuw, David Avigan, Kyle Jensen, Brigitte Demers, Timothy Wagenaar, Gu Mi, Samira Ziti-Ljajic, Dobrin Draganov, Giovanni Abbadessa, Andrew H Wei

Blood (2022) 140 (Supplement 1): 7476–7477.

https://doi.org/10.1182/blood-2022-166000

Published: 2022

Journal Articles

Sinusoidal Obstruction Syndrome in Adult Patients with B-Cell Acute Lymphoblastic Leukemia Treated with Inotuzumab Prior to Hematopoietic Stem Cell Transplantation

Blood (2022) 140 (Supplement 1): 10449–10450.

https://doi.org/10.1182/blood-2022-165839

Published: 2022

Journal Articles

Interim Results of a Phase 1/2 Study of Pembrolizumab Combined with Blinatumomab in Patients with Relapsed/Refractory (r/r) ALL

Blood (2022) 140 (Supplement 1): 8985–8986.

https://doi.org/10.1182/blood-2022-170279

Published: 2022

Journal Articles

Long Term Outcomes of Patients with Chronic Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation in the Era of Oral Tyrosine Kinase Inhibitors

Blood (2022) 140 (Supplement 1): 12945–12946.

https://doi.org/10.1182/blood-2022-170009

Published: 2022

Journal Articles

Novel Salvage Therapies Are Highly Effective in Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) with Philadelphia (Ph)-like Fusions

Blood (2022) 140 (Supplement 1): 6020–6022.

https://doi.org/10.1182/blood-2022-158288

Published: 2022

Journal Articles

Safety and Tolerability of AZD0466 As Monotherapy for Patients with Advanced Hematological Malignancies. Preliminary Results from an Ongoing Phase I/II Trial

Shukaib Arslan, Shaun Fleming, Nitin Jain, Giovanni Martinelli, Anthony S. Stein, James S. Blachly, Ashish Bajel, Antonio Curti, Giovanni Marconi, Giulia Fabbri, Yotvat Marmor, Shringi Sharma, Nairouz Elgeioushi, Natalia Couto-Francisco, Jamal Saeh, Raoul Tibes, Fathima Zumla Cader, Marina Konopleva

Blood (2022) 140 (Supplement 1): 9091–9093.

https://doi.org/10.1182/blood-2022-166192

Published: 2022

Journal Articles

Evaluation of 5-Day Vs. 10-Day Decitabine in Combination with Venetoclax in Newly Diagnosed AML Patients Ineligible for Induction Chemotherapy

Blood (2022) 140 (Supplement 1): 9039–9040.

https://doi.org/10.1182/blood-2022-170867

Published: 2022

Journal Articles

Consolidation with Allogeneic Hematopoietic Cell Transplant Improved Survival Outcomes of Adults with Relapsed / Refractory Acute Lymphoblastic Leukemia Following Response to Memory-Enriched CD19CAR T Cells

Blood (2022) 140 (Supplement 1): 4615–4616.

https://doi.org/10.1182/blood-2022-163439

Published: 2022

Journal Articles

Adct-602, a CD22 Targeting Antibody Drug Conjugate Bound to PBD Toxin in Adult Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: A Phase 1 Trial

Nitin Jain, Elias Jabbour, Ibrahim Aldoss, Marina Konopleva, Nicholas Short, Anthony S. Stein, Naveen Pemmaraju, Philip A. Thompson, Farhad Ravandi, Hagop Kantarjian

Blood (2022) 140 (Supplement 1): 521–522.

https://doi.org/10.1182/blood-2022-170730

Published: 2022

Journal Articles

Myeloablative Vs Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation in Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia

Blood (2022) 140 (Supplement 1): 12819–12820.

https://doi.org/10.1182/blood-2022-164657

Published: 2022

Journal Articles

Promising Safety and Efficacy Results from an Ongoing Phase 1b Study of Pembrolizumab Combined with Decitabine in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Vaibhav Agrawal, Cindy Croslin, Asuscena L. Beltran, Jianying Zhang, Joycelynne Palmer, Quy Huynh-Tran, Rochelle Hernandez, Sandra Thomas, Marjorie Robbins, Ahmed Aribi, Haris Ali, Anthony S. Stein, Elizabeth L. Budde, Monzr M. Al Malki, Guido Marcucci

Blood (2022) 140 (Supplement 1): 6235–6236.

https://doi.org/10.1182/blood-2022-165894

Published: 2022

Journal Articles

Effective Cell Dose and Functional Attributes of Azercabtagene Zapreleucel (azer-cel; PBCAR0191) Associate with Allogeneic CAR T-Cell Safety and Efficacy in Patients with Relapsed/Refractory B-Cell Lymphoma

Blood (2022) 140 (Supplement 1): 4588–4589.

https://doi.org/10.1182/blood-2022-165311

Published: 2022

Journal Articles

Outcomes Post-Allogeneic Hematopoietic Cell Transplantation Relapse in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Blood (2022) 140 (Supplement 1): 10568–10570.

https://doi.org/10.1182/blood-2022-163652

Published: 2022

Journal Articles

Renal Impairment Adversely Impacts Melphalan-Induced Severe GvHD- and GI Toxicity- Free Survival (MGTFS) in Patients Undergoing Reduced Intensity Allogeneic Peripheral Blood Stem Cell Transplantation

Blood (2022) 140 (Supplement 1): 7595–7596.

https://doi.org/10.1182/blood-2022-170655

Published: 2022

Journal Articles

Tocilizumab for the Management of Cytokine Release Syndrome after Haploidentical Hematopoietic Transplant with Post-Transplant Cyclophosphamide-Based GvHD Prophylaxis

Janny M. Yao, Hanna Kim, Dongyun Yang, Sally Mokhtari, Salman Otoukesh, Shukaib Arslan, Idoroenyi Amanam, Brian J Ball, Paul B. Koller, Amandeep Salhotra, Ahmed Aribi, Andrew S. Artz, Ibrahim Aldoss, Haris Ali, Anthony S. Stein, Guido Marcucci, Stephen J Forman, Ryotaro Nakamura, Monzr M. Al Malki

Blood (2022) 140 (Supplement 1): 7580–7582.

https://doi.org/10.1182/blood-2022-167713

Published: 2022

NARROW

North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need

Phase IIa Study of Adding Itacitinib to Tacrolimus/Sirolimus Gvhd Prophylaxis after Fludarabine/Melphalan-Based Conditioning Hematopoietic Cell Transplantation for Acute Leukemias, Myelodysplastic Syndrome, or Myelofibrosis

Outcome of Patients Undergoing Hematopoietic Cell Transplantation for TP53-Mutated Acute Leukemias and MDS: Effect of Conditioning and GvHD Prophylaxis Regimens Intensity

Tagraxofusp, an Anti-CD123 Therapy, in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm and Prior or Concomitant Hematologic Malignancies: Subgroup Analysis of a Pivotal Trial

A Phase 1b Study of IDH Inhibition with Enasidenib and MEK Inhibition with Cobimetinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia Who Have Co-Occurring IDH2 and RAS Signaling Gene Mutations

An Open-Label, First-in-Human, Dose-Escalation Study of SAR443579 Administered As Single Agent By Intravenous Infusion in Patients with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-Cell Acute Lymphoblastic Leukemia (B-ALL) or High-Risk Myelodysplasia (HR-MDS)

Sinusoidal Obstruction Syndrome in Adult Patients with B-Cell Acute Lymphoblastic Leukemia Treated with Inotuzumab Prior to Hematopoietic Stem Cell Transplantation

Interim Results of a Phase 1/2 Study of Pembrolizumab Combined with Blinatumomab in Patients with Relapsed/Refractory (r/r) ALL

Long Term Outcomes of Patients with Chronic Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation in the Era of Oral Tyrosine Kinase Inhibitors

Novel Salvage Therapies Are Highly Effective in Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) with Philadelphia (Ph)-like Fusions

Safety and Tolerability of AZD0466 As Monotherapy for Patients with Advanced Hematological Malignancies. Preliminary Results from an Ongoing Phase I/II Trial

Evaluation of 5-Day Vs. 10-Day Decitabine in Combination with Venetoclax in Newly Diagnosed AML Patients Ineligible for Induction Chemotherapy

Consolidation with Allogeneic Hematopoietic Cell Transplant Improved Survival Outcomes of Adults with Relapsed / Refractory Acute Lymphoblastic Leukemia Following Response to Memory-Enriched CD19CAR T Cells

Adct-602, a CD22 Targeting Antibody Drug Conjugate Bound to PBD Toxin in Adult Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: A Phase 1 Trial

Myeloablative Vs Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation in Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia

Promising Safety and Efficacy Results from an Ongoing Phase 1b Study of Pembrolizumab Combined with Decitabine in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Effective Cell Dose and Functional Attributes of Azercabtagene Zapreleucel (azer-cel; PBCAR0191) Associate with Allogeneic CAR T-Cell Safety and Efficacy in Patients with Relapsed/Refractory B-Cell Lymphoma

Outcomes Post-Allogeneic Hematopoietic Cell Transplantation Relapse in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Renal Impairment Adversely Impacts Melphalan-Induced Severe GvHD- and GI Toxicity- Free Survival (MGTFS) in Patients Undergoing Reduced Intensity Allogeneic Peripheral Blood Stem Cell Transplantation

Tocilizumab for the Management of Cytokine Release Syndrome after Haploidentical Hematopoietic Transplant with Post-Transplant Cyclophosphamide-Based GvHD Prophylaxis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only